XSHG
600056
Market cap1.98bUSD
Jul 09, Last price
9.00CNY
1D
-1.10%
1Q
-17.96%
Jan 2017
-33.77%
Name
China Medicine Health Industry Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Meheco Group Co., Ltd. functions as a pharmaceutical company with a presence across both domestic Chinese and international markets. The enterprise's primary operations involve the import and export of various national Chinese medicines and health-related items, as well as the production and commercial distribution of pharmaceutical and wellness solutions. It also oversees a network of retail pharmacies. The company's extensive product catalog includes bulk pharmaceutical chemicals, such as those from antibiotic fermentation and chemical synthesis, along with finished dosage forms like tablets, injections, and capsules. It supplies a broad range of antibiotics and medications specifically formulated for cardiovascular, cerebrovascular, chronic, and diabetic conditions. Additionally, its offerings encompass antiviral and anti-infectious agents, gastrointestinal remedies, non-steroidal anti-inflammatory drugs, anti-allergic treatments, specialized botanical products, Western medicine preparations, traditional Chinese patent medicines, processed herbal ingredients, medical equipment and supplies, biological products and their raw materials, various chemical raw materials, and nutritional and general healthcare products. Furthermore, China Meheco Group Co., Ltd. engages in the cultivation, processing, warehousing, and transportation of medicinal herbs, including prominent examples such as ginseng, licorice, ephedra, rhubarb, rheum officinale, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, established in 1984, is headquartered in Beijing, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||